Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density

Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

1999 • 2,473 citations

Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

1995 • 2,293 citations

On closed testing procedures with special reference to ordered analysis of variance

1976 • 1,334 citations

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.

1991 • 1,013 citations

Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis

1990 • 966 citations

Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal Osteoporosis

1990 • 949 citations

Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin

1999 • 887 citations

Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials

2001 • 825 citations

Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling

1995 • 366 citations

Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.

2000 • 366 citations

Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis

1997 • 288 citations

Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment

1994 • 281 citations

Comparison of the distribution of 3H-alendronate and 3H-Etidronate in rat and mouse bones

1996 • 252 citations

Universal Standardization of Bone Density Measurements: A Method with Optimal Properties for Calibration Among Several Instruments

1997 • 230 citations

Three Monthly Intravenous Injections of Ibandronate in the Treatment of Postmenopausal Osteoporosis

1997 • 192 citations

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis

1996 • 190 citations

Bone Morphogenetic Protein: The Molecularization of Skeletal System Development

1997 • 170 citations

A Dose-Finding Study of Zoledronate in Hypercalcemic Cancer Patients

1999 • 154 citations

The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study

1996 • 153 citations

Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause

1994 • 113 citations

Patient Noncompliance with Hormone Replacement Therapy

1998 • 90 citations

Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis

1991 • 74 citations

Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis

1994 • 53 citations

Compliance to bisphosphonates - a population-based study using a drug prescription database

2000 • 3 citations

Cited By (0)

Loading...